EML4 and neoplasm: Consistently, ALK inhibition with crizotinib reversed the stem-like phenotypes of EML4-ALK+ tumor cells, suggesting ALK signaling is a central molecular axis in the stem-like phenotype of EML4-ALK+ tumor cells.